AP Biosciences, Inc. Stock

6945

TW0006945009

Biotechnology & Medical Research

End-of-day quote Taipei Exchange 28/08/2026			5-day change	1st Jan Change
104.00 ^TWD	-2.80%		+2.46%	-42.22%

08-12	AP Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Valuation : AP Biosciences, Inc.

Market Cap	10.09B 319M 275M 258M 235M 443M 30.42B 446M 3.06B 1.19B 15.36B 1.2B 1.17B 51.04B	P/E 2024	-8.86x	P/E 2025	-34.4x
Enterprise Value	8.98B 284M 245M 229M 209M 394M 27.07B 397M 2.72B 1.06B 13.67B 1.07B 1.04B 45.42B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	52.56%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : AP Biosciences, Inc.

08-12	AP Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies	CI
03-31	AP Biosciences, Inc. has filed an IPO in the amount of TWD 1.2562 billion.	CI
03-23	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	AP Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/08/25	AP Biosciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
14/05/25	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/04/25	AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual Meeting	CI
22/04/25	AP Biosciences Doses First Patient In Phase 1/2 Clinical Trials Of AP402 For HER2+ Cancer Patients	RE
22/04/25	AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients	CI
21/04/25	AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting	CI
13/08/24	AP Biosciences Inc Reports Earnings Results for the Half Year Ended June 30, 2024	CI

More news

Press Releases : AP Biosciences, Inc.

24/07/25

Designing antibodies to think before they bind

More press releases

Managers and Directors : AP Biosciences, Inc.

Manager	Title	Age	Since
Jeng-Horng Her CEO	Chief Executive Officer	-	27/05/2013
Shu Cheng Lin DFI	Director of Finance/CFO	-	18/10/2022
Wan Ju Tseng ADM	Chief Administrative Officer	-	18/10/2022

Director	Title	Age	Since
Jeng-Horng Her BRD	Director/Board Member	-	09/11/2022
Ming-Tain Lai BRD	Director/Board Member	-	04/06/2019
Hui Chin Tseng BRD	Director/Board Member	-	04/06/2021

More insiders

AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	NT$104.00	-2.80%	171,712
27/08/26	NT$107.00	+5.42%	608,366
26/08/26	NT$101.50	+1.50%	169,359
25/08/26	NT$100.00	-1.48%	93,686
24/08/26	NT$101.50	0.00%	235,949

End-of-day quote Taipei Exchange

More quotes

Stock Market
Stocks
6945 Stock

The best tools reserved for subscribers to boost the performance of your investments!

1 day	-2.80%
1 week	+2.46%
Current month	+19.27%
1 month	+14.41%
3 months	-14.75%
6 months	-41.24%
Current year	-42.22%

1 week	99.6	109
1 month	86.1	116.5
Current year	86.1	236
1 year	86.1	236
3 years	36.3	236
5 years	36.3	236
10 years	36.3	236

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AP BIOSCIENCES, INC.	-2.80%	+2.46%	-11.86%	+98.10%	319M
WUXI APPTEC CO., LTD.	-1.59%	-3.35%	+64.49%	+98.69%	69.54B
ARGENX SE	-1.34%	-0.75%	+48.56%	+90.63%	64.97B
BIONTECH SE	-8.37%	-12.43%	+0.14%	-15.42%	25.64B
INSMED INCORPORATED	-2.35%	-5.75%	-12.17%	+448.29%	25.89B
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+63.18%	+11.93%	26.51B
PHARMAESSENTIA CORPORATION	-0.96%	+10.36%	+278.86%	+438.78%	20.22B
GENMAB A/S	-0.51%	+0.23%	+33.71%	-18.02%	19.98B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.33%	+531.29%	15.69B
EXELIXIS, INC.	-1.47%	+0.68%	+43.67%	+145.49%	13.49B
Average	-2.10%	-1.49%	+52.19%	+182.98%	28.22B
Weighted average by Cap.	-1.93%	-1.50%	+57.07%	+152.76%

	2024	2025
Net sales	-	-
Net income	-423M -13.37M -11.52M -10.8M -9.86M -18.56M -1.27B -18.7M -128M -50M -644M -50.18M -49.09M -2.14B	-445M -14.06M -12.12M -11.37M -10.38M -19.53M -1.34B -19.68M -135M -52.61M -677M -52.79M -51.64M -2.25B
Net Debt	-1.47B -46.5M -40.09M -37.58M -34.32M -64.57M -4.44B -65.07M -446M -174M -2.24B -175M -171M -7.44B	-1.11B -35.14M -30.3M -28.4M -25.93M -48.79M -3.35B -49.17M -337M -131M -1.69B -132M -129M -5.62B

AP Biosciences, Inc. Stock

Stocks

6945

TW0006945009

Biotechnology & Medical Research

Valuation : AP Biosciences, Inc.

Chart: AP Biosciences, Inc.

Latest news : AP Biosciences, Inc.

Press Releases : AP Biosciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : AP Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes